 
 |
|
Cougar Biotechnology Presents Positive CB7630 (Abiraterone Acetate) Phase II Data at ASCO Annual Meeting
Date: May 28, 2009
Client: Cougar Biotechnology
Summary: Los Angeles, CA - Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced that results from ongoing Phase II clinical trials of Cougar's investigational drug CB7630 (abiraterone acetate) were presented at the 2009 ASCO Annual Meeting that is currently taking place in Orlando, Florida. The data were released today in three poster presentations.
|
|
|
|
 |
|
Results and Additional Analyses From Efficacy and Safety Study of Corthera's Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Date: May 28, 2009
Client: Corthera
Summary: SAN MATEO‚ Calif. – Results and additional analyses from the Phase II portion of a Phase II/III clinical trial of Corthera’s investigational drug relaxin for the treatment of acute heart failure will be presented at the Heart Failure Congress, the annual meeting of the Heart Failure Association of the European Society of Cardiology in Nice, France.
|
|
|
|
 |
|
Delivering Asthma Drugs With Nanoparticles
Date: May 25, 2009
Client: Savara Pharmaceuticals
Summary: Despite medical advancements in drugs and delivery devices for asthma and allergy sufferers, some patients are not getting appropriate dosages. But new advances are being worked on that could improve care for many through nanotechnology. Rob Neville, executive chairman of Savara Pharmaceuticals, tells the Chicago Tribune's Bruce Japsen about the use of nanotechnology as an emerging way to administer drugs more effectively for improved respiratory care.
|
|
|
|
|
|
|
Pulmonary Aerodynamics
Date: May 2009
Client: Savara Pharmaceuticals
Summary: Savara, Inc., reformulates successful drugs for us in standard inhalable devices, by engineerign the nano "whiffle ball" out of the drug itself. Executive chairman Rob Neville explains in a pharma QpD Podcast.
|
|
|
|
|
|
|
Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
Date: May 21, 2009
Client: Cougar Biotechnology
Summary: NEW BRUNSWICK, N.J., and LOS ANGELES - Johnson & Johnson (NYSE: JNJ) and Cougar Biotechnology, Inc. (Nasdaq: CGRB), a development stage biopharmaceutical company with a specific focus on oncology, today announced a definitive agreement whereby Cougar Biotechnology will be acquired for approximately $1.0 billion in a cash tender offer.
|
|
|
|
 |
|
In the Wake of 9/11: Research in Pulmonary Fibrosis
Date: May 18, 2009
Client: Amira Pharmaceuticals
Summary: In the United States, almost 50,000 new cases of pulmonary fibrosis — a disease that causes progressive scarring of the lung tissue — are diagnosed annually, including among some first responders to Ground Zero in New York. There are no treatment options, but early research has begun in hopes of one day treating this deadly disease, as Bob Baltera, chief executive officer of Amira Pharmaceuticals explains to host Bruce Japsen. Amira Pharmaceuticals is a San Diego-based company focused on the discovery and early development of compounds to treat inflammatory disease.
|
|
|
|
 |
|
GlobeImmune and Celgene Corporation Announce Strategic Global Oncology Alliance
Date: May 15, 2009
Client: GlobeImmune
Summary: LOUISVILLE, Colo. & SUMMIT, N.J. - GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery, development and commercialization of multiple product candidates based on powerful, targeted molecular immunotherapy for the treatment of cancer.
|
|
|
|
 |
|
Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
Date: May 14, 2009
Client: Regulus Therapeutics
Summary: CARLSBAD, Calif. - Regulus Therapeutics Inc. today announced that it achieved the initial milestone with GlaxoSmithKline (GSK) as part of their ongoing worldwide strategic alliance established to discover, develop and market novel microRNA-based therapeutics to treat inflammatory diseases. The two companies are working to identify drugs directed at four different microRNA targets related to inflammatory disease. Regulus has now reached an important discovery milestone, which triggered a payment, concurrent with the first demonstration of a pharmacological effect in immune cells by specific microRNA inhibition. Scientists successfully delivered specific microRNA inhibitors, known as anti-miRs, to mice and clearly identified changes in expression of the genes regulated by the microRNA in immune cells.
|
|
|
|
 |
|
Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval to Proceed with Phase 3 Development of Onalta™
Date: May 14, 2009
Client: Molecular Insight
Summary: Cambridge, MA - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced that the European Medicines Agency (EMEA) has approved its Phase 3 protocol for Onalta (Yttrium-90 edotreotide). Onalta is the Company’s lead radiotherapeutic product candidate under development for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. The compound has shown the potential to selectively deliver lethal radiation to cancer cells. The proposed Phase 3 trial will confirm that administration of Onalta results in stabilization, regression or complete remission of the carcinoid tumor, and improves carcinoid-related symptoms when compared to a high-dose regimen of the current standard therapy for this disease, Sandostatin®. With EMEA’s approval of its proposed Phase 3 protocol in hand, Molecular Insight can proceed with the final clinical trial that will position Onalta for marketing authorization in the EU.
|
|
|
|
|
|
|
Molecular Insight Pharmaceuticals Expands Management Team by Appointing Daniel L. Peters as President and Chief Executive Officer
Date: May 13, 2009
Client: Molecular Insight
Summary: Cambridge, MA - The Board of Directors of Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that Daniel L. Peters has been appointed President and Chief Executive Officer. Mr. Peters was also elected to Molecular Insight's Board of Directors. Mr. Peters assumes the positions that had been held by John W. Babich, Ph.D., a Company founder, who will now serve as Executive Vice President, Chief Scientific Officer and President of Research and Development and continue as a member of the Board of Directors.
|
|
|
|
 |
|
Debiopharm and Mepha sign distribution agreement for Pamorelin® LA 1-, 3- and 6-month formulations
Date: May 11, 2009
Client: Debiopharm Group
Summary: Lausanne and Aesch, Switzerland - Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, and Mepha Pharma A.G. (Mepha), announce the signature of an exclusive distribution agreement in Switzerland, for the 1- ,3- and 6 month formulations of Pamorelin® LA. The product, which contains the active substance triptorelin pamoate,
is indicated for the treatment of prostate
cancer, endometriosis, and female infertility. The launch of Pamorelin® LA in Switzerland is expected in mid-2009.
|
|
|
|
|
|
|
Cougar Biotechnology to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Date: May 5, 2009
Client: Cougar Biotechnology
Summary: Los Angeles, Calif. - Cougar Biotechnology, Inc. (NASDAQ: CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, at 11:20 a.m. EDT at The Palace Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar’s current clinical development programs.
|
|
|
|
 |
|
Acadia Pharmaceuticals and Biovail form Collaboration to Develop and Commercialize Pimavanserin in North America
Date: May 4, 2009
Client: Acadia
Summary: SAN DIEGO, CA – ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation, to co-develop and commercialize pimavanserin, ACADIA’s proprietary and selective 5-HT2A inverse agonist, in the United States and Canada. ACADIA retains rights to pimavanserin in the rest of the world. Pimavanserin is a new chemical entity (NCE) currently in Phase III development as a treatment for Parkinson’s disease psychosis.
|
|
|
|
 |
|
Fovea Reports Positive Results with PrednisporinTM in Persistent Allergic Conjunctivitis
Date: May 4, 2009
Client: Fovea Pharmaceuticals
Summary: Paris, France - Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of PrednisporinTM (FOV1101) in patients with persistent allergic conjunctivitis. PrednisporinTM had the same efficacy and a better safety profile (no increase in intra-ocular pressure) than PredForteTM, a prescription drug with a 10 fold higher dose of prednisolone acetate, in patients treated for the signs and symptoms (itching and redness) of persistent ocular allergic inflammation. A one-week pre-treatment with PatadayTM (an anti-histamine) had negligible effect on these parameters in this patient population.
|
|
|
|
|
